scholarly journals The Clinical Significance of Fibrin Monomers

2018 ◽  
Vol 118 (11) ◽  
pp. 1856-1866 ◽  
Author(s):  
Majed Refaai ◽  
Paul Riley ◽  
Tatsiana Mardovina ◽  
Phoenix Bell
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Ischaemic Stroke ◽  
Acute Ischaemic Stroke ◽  
High Sensitivity ◽  
Vein Thrombosis ◽  
Deep Vein ◽  
Test Probability ◽  
Definitive Role

Introduction Fibrin monomer (FM) concentrations reflect pro-thrombin activity and have the potential to predict thrombotic events relatively earlier than other haemostatic markers. Most often, FM are compared with D-dimer (DD) as increased DD have been documented in disseminated intravascular coagulation (DIC), deep vein thrombosis (DVT) and pulmonary embolism. Although DD have a high sensitivity and negative predictive value, their specificity is much lower depending on the assay chosen, clinical pre-test probability and patient condition. There are limited reports investigating the utility of FM in hyper-coagulable patients. Methods We performed a literature search of FM concentrations in hyper-coagulable patients including those with DIC, acute ischaemic stroke, atrial fibrillation, acute myocardial infarction, venous thromboembolism (VTE) and cancer, as well as those who are pregnant or undergoing surgery. Results FM were increased in patients with DIC and those with malignancy. In contrast, detection of VTE or post-operative DVT development is likely enhanced using both FM and DD concentrations. Similarly, measuring FM concentrations with other biomarker levels may be more beneficial in patients suffering an acute myocardial infarction or acute ischaemic stroke. Lastly, FM concentrations vary substantially throughout pregnancy with no definitive role of FM as of yet. Conclusion Utilizing FM concentrations to assess hyper-coagulable patients seems promising; however, there are limitations including variations in FM cut-off values, the effect of patient medications and the timing of FM measurement relative to an acute event. Thus, further investigation is required before a true advantage for FM as a haemostatic marker can be established.

Kinetics of high-sensitivity cardiac troponin T or troponin I compared to creatine kinase in patients with revascularized acute myocardial infarction

2015 ◽  
Vol 53 (5) ◽  
Author(s):  
Kamila Solecki ◽  
Anne Marie Dupuy ◽  
Nils Kuster ◽  
Florence Leclercq ◽  
Richard Gervasoni ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Cardiac Troponin ◽  
Troponin I ◽  
Troponin T ◽  
High Sensitivity ◽  
Cardiac Troponin T ◽  
Significant Difference ◽  
Kinetics Of

AbstractCardiac biomarkers are the cornerstone of the biological definition of acute myocardial infarction (AMI). The key role of troponins in diagnosis of AMI is well established. Moreover, kinetics of troponin I (cTnI) and creatine kinase (CK) after AMI are correlated to the prognosis. New technical assessment like high-sensitivity cardiac troponin T (hs-cTnT) raises concerns because of its unclear kinetic following the peak. This study aims to compare kinetics of cTnI and hs-cTnT to CK in patients with large AMI successfully treated by percutaneous coronary intervention (PCI).We prospectively studied 62 patients with anterior AMI successfully reperfused with primary angioplasty. We evaluated two consecutive groups: the first one regularly assessed by both CK and cTnI methods and the second group by CK and hs-cTnT. Modeling of kinetics was realized using mixed effects with cubic splines.Kinetics of markers showed a peak at 7.9 h for CK, at 10.9 h (6.9–12.75) for cTnI and at 12 h for hs-cTnT. This peak was followed by a nearly log linear decrease for cTnI and CK by contrast to hs-cTnT which appeared with a biphasic shape curve marked by a second peak at 82 h. There was no significant difference between the decrease of cTnI and CK (p=0.63). CK fell by 79.5% (76.1–99.9) vs. cTnI by 86.8% (76.6–92.7). In the hs-cTnT group there was a significant difference in the decrease by 26.5% (9–42.9) when compared with CK that fell by 79.5% (64.3–90.7).Kinetic of hs-cTnT and not cTnI differs from CK. The role of hs-cTnT in prognosis has to be investigated.

scholarly journals ROLE OF PROPHYLACTIC ANTI COAGULANTS AND ANTI PLATELETS TO REDUCE THE INCIDENCE OF THROMBOSIS, STROKE, MYOCARDIAL INFARCTION IN ASYMPTOMATIC PATIENTS OF COVID19

2021 ◽  
pp. 14-16
Author(s):  
J Mariano Anto Brunomascarenhas
Keyword(s):  
Myocardial Infarction ◽  
Pulmonary Embolism ◽  
Deep Vein Thrombosis ◽  
The Body ◽  
Vein Thrombosis ◽  
Asymptomatic Patients ◽  
Embolism And Thrombosis ◽  
Deep Vein ◽  
Serial Evaluation

BACKGROUND: As we are in the middle of the second year of the COVID19 Pandemic,we are observing an increased incidence of conditions like Cerebrovascular Accidents, Ischemic Heart Disease, Myocardial Infarction, Deep Vein Thrombosis,Pulmonary Embolism,and Thrombosis of Other Vessels. MATERIALS AND METHODS: Literature Review and Analysis of Coagulation Profiles of Patients in the past 1 year treated by the author was done. RESULTS AND CONCLUSIONS: 1. COVID19 is not just an infectious disease, but also an Immune Disease. The Immune Part can also happen in Asymptomatic Patients and those who got the vaccine. 2. Most of the disease processes in the body start after the virus has been cleared from the throat. The vigil against complications must not stop when the Throat Swab becomes negative or even when the patient is discharged but must continue for months till all the disease processes stop. 3.It is recommended that: a.Initial Evaluation with PT, aPTT, INR is done for: I.Those suffering from COVID 19 who have not undergone D Dimer evaluation ii.Those recovering from COVID 19. iii.Those likely to have had COVID 19 (based on the symptoms),but the infection was not documented. iv.Those likely to have had asymptomatic COVID 19 (contacts of COVID19 infected patients) v.Those planning to take Vaccines for COVID19. b.An Abnormal Value in PT,aPTT,INR may be managed with appropriate Drugs like Aspirin,Clopidogrel,Dipyridamole, Ticlopidine, Rivaroxaban, Dabigatran, Apixaban, Edoxaban, Heparin, Low Molecular Weight Heparin, Warfarin, and other drugs. c. Serial Evaluation of PT, aPTT, INR be done after 1 month, 3 months, 6 months (and even at more frequent intervals if indicated) and the drugs are added or removed,the dosage of the drugs is increased or reduced based on the results. d.Standard Indication of IVC Filter may be followed. 4.It is the knowledge of the pathogenesis of Thrombosis that is crucial in the prevention and management of Stroke, Heart Attack, Deep Vein Thrombosis, and Pulmonary Embolism rather than fancy gadgets, expensive tests, and exotic drugs.

On the Significance of Antithrombin-III, α2-Macroglobulin, α2-Antiplasmin, Histidine-Rich Glycoprotein, and Protein C in Patients with Acute Myocardial Infarction and Deep Vein Thrombosis

1985 ◽  
Vol 54 (02) ◽  
pp. 503-505 ◽  
Author(s):  
Jørgen Gram ◽  
Jørgen Jespersen
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Deep Vein Thrombosis ◽  
Longitudinal Study ◽  
Protein C ◽  
Antithrombin Iii ◽  
Clinical Signs ◽  
Vein Thrombosis ◽  
Α2 Macroglobulin ◽  
Deep Vein

SummaryIn a longitudinal study the plasma levels of antithrombin-III, α2-macroglobulin, α2-antiplasmin, histidine-rich glycoprotein, and protein C were followed in two groups of patients with acute myocardial infarction (AMI), one with and one without deep vein thrombosis (DVT). None of the sequentially studied periods revealed significant differences between the two groups of patients. However, small but consistently higher levels of histidine-rich glycoprotein in patients with DVT suggested the existence among patients submitted for myocardial infarction of a subgroup with increased thrombophilic potential. It was concluded that the inhibitors studied are of little value as possible indicators of the presence of DVT at early stages of the disease when clinical signs are absent and when antithrombotic prophylaxis should preferably be initiated.

Venous Function of the Leg in Patients with Acute Myocardial Infarction

1989 ◽  
Vol 4 (2) ◽  
pp. 83-89 ◽  
Author(s):  
Asbjörn Kierkegaard ◽  
Lars Norgren ◽  
Ulf Thilen
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Deep Vein Thrombosis ◽  
Severe Disease ◽  
Venous Outflow ◽  
Vein Thrombosis ◽  
Venous Volume ◽  
Venous Function ◽  
Deep Vein ◽  
Anterior Infarction

Venous volume and venous outflow of the calf were studied with strain gauge plethysmography in 50 unselected patients with an acute myocardial infarction. These parameters increased during the first days if the course of the infarction was uncomplicated. In complicated myocardial infarction however, no such increase was registered. In patients without complications, venous volume and venous outflow were higher in those who were mobilized compared to inactive ones, and patients with an anterior infarction had higher values than those with other locations of their myocardial infarction. Deterioration of venous function apparently is associated with more severe disease, and may predispose to a further complication, deep vein thrombosis.

Sign in / Sign up

Export Citation Format

Share Document